(CercleFinance.com) – The management of Moderna published yesterday afternoon an update of its sales estimates for 2021 as well as its ambitions for 2022.
‘We retain: 1/2021 sales should be around $ 17.5 billion, i.e. in the upper range of the guidance announced in Q3 (between $ 15 and $ 18 billion) 2 / Regarding 2022, the management has revised its initial orientation upwards. In fact, the purchase agreements for this new year relate to sales of around $ 18.5 billion (vs. $ 17 billion previously) accompanied by options of around $ 3.5 billion (vs. $ previously.) ‘indicates Oddo.
Oddo reiterates his Outperformance advice on the stock with a price target of $ 440.
‘The pressure at the end of last year on the title (post results of phase 1 in the seasonal flu) seems to us a good opportunity for strengthening. The year 2022 should still be guided by the evolution of the pandemic. However, this development should give way to development opportunities for the group with an estimated cash flow of $ 24 billion this year, ‘adds Oddo.
Copyright © 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute decision support for investors. Cercle Finance cannot be held liable directly or indirectly following the use of information and analyzes by readers. It is recommended that anyone who is not informed to consult a professional adviser before any investment. This indicative information in no way constitutes an invitation to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
